 "sun pharma")
Sun Pharma’s better-than-expected June quarter performance has improved the sentiment on the Street, leading to a 3.71 per cent gain in the stock on a day when broader indices were down over 1.5 per cent.
The US market, which accounts for 36 per cent of revenue, saw a 12 per cent growth in constant currency terms. The sales numbers include contribution from a significant business of generic supply to a customer and Taro Sun’s US subsidiary, which was up 4 per cent. Analysts say growth was robust if one were to exclude the numbers from the Taro business. Sun is
